Stocks · News reference
Revvity Raises FY2026 Adj EPS Guidance from $5.20-$5.30 to $5.30-$5.40 vs $5.27 Est; Raises FY2026 Sales Guidance from $2.810B-$2.840B to $2.830B-$2.860B vs $2.858B Est
Revvity (NYSE:RVTY) raises FY2026 Adj EPS guidance from $5.20-$5.30 to $5.30-$5.40 vs $5.27 analyst estimate. Raises FY2026 sales outlook from $2.810 billion-$2.840 billion to $2.830 billion-$2.860 billion vs $2.858
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Global Multiplex Assays Market 2026 Edition - Consumables Dominate Multiplex Assays with 68% Market Share
The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with 34% market share, while Asia Pacific is the fastest-growing region at 15.5% CAGR. Consumables dominate with 68% market share, and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, and laboratory automation.
RBC Capital Initiates Coverage On Revvity with Sector Perform Rating, Announces Price Target of $135
RBC Capital analyst Dan Leonard initiates coverage on Revvity (NYSE:RVTY) with a Sector Perform rating and announces Price Target of $135.
Evercore ISI Group Maintains Outperform on Revvity, Raises Price Target to $126
Evercore ISI Group analyst Vijay Kumar maintains Revvity (NYSE:RVTY) with a Outperform and raises the price target from $125 to $126.